120 entries across the Exam 3 lectures, each citing its slide, with black box warnings shaded. Companion to the contraindications and indications charts.
| Drug or class | Side effects | Monitoring & what to watch | System | Source |
|---|---|---|---|---|
| Loop diuretics | ||||
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Volume depletion through reflex mechanisms, with azotemia (a rise in blood urea nitrogen). Excess diuresis can cause hypotension and cardiovascular collapse. | Check weight, blood pressure and orthostatic symptoms; check blood urea nitrogen and creatinine. | Renal / Fluid | L9 slide 18 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acidBlack box | Volume depletion when given in excess. Added background: furosemide, bumetanide and ethacrynic acid carry an FDA boxed warning (black box) for profound diuresis with water and electrolyte depletion; torsemide carries none. | Start at the lowest effective amount and watch fluid status and electrolytes closely. | Renal / Fluid | L9 slide 18 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Hypokalemia (potassium loss) with the risk of cardiac arrhythmias. | Monitor serum potassium; a potassium-sparing partner or supplement may be added. Highest risk with digoxin. | Electrolytes / Cardiovascular | L9 slide 18 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Loss of calcium and magnesium in the urine (hypocalcemia and hypomagnesemia). | Monitor magnesium and calcium with long-term use. | Electrolytes | L9 slide 13 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Hyponatremia, which can lead to seizures. | Monitor serum sodium. | Electrolytes / Neurologic | L9 slide 18 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Hyperglycemia (a diabetogenic effect): low potassium impairs insulin release, catecholamines are released reflexively (alpha-2 decreases insulin release, beta-2 increases glycogenolysis) and peripheral glucose uptake is impaired. | Monitor blood glucose in patients with diabetes. | Metabolic | L9 slide 18 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Contraction alkalosis: mild metabolic alkalosis from volume depletion and, mainly, enhanced hydrogen ion secretion. | Watch serum bicarbonate. | Acid-base | L9 slide 18 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Hyperuricemia and gout: less uric acid is excreted and the plasma is concentrated by the lost volume. | Ask about a history of gout; a flare may follow starting the drug. | Metabolic / Musculoskeletal | L9 slide 18 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Ototoxicity: damages hair cells in the cochlea (hearing loss). Aminoglycosides potentiate it. | Ask about tinnitus or hearing change; avoid combining with other ear-toxic drugs. | Sensory | L9 slide 18 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Allergic reactions: rash and photosensitivity. | Counsel on sun protection and to report a rash. | Dermatologic | L9 slide 18 |
| Loop diuretics furosemide, bumetanide, torsemide, ethacrynic acid | Mild hyperlipidemia (sympathetic activity raises triglycerides) and reflex activation of renin-angiotensin, aldosterone and antidiuretic hormone. | Lipids are a minor concern; the reflex activation explains a weakened diuretic effect. | Metabolic / Endocrine | L9 slide 16 |
| Thiazide diuretics | ||||
| Thiazide diuretics chlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide | Volume depletion with reflex sympathetic activation and increased renin-angiotensin, aldosterone and antidiuretic hormone activity; an acute drop in glomerular filtration rate. | Check weight, blood pressure and kidney function. | Renal / Fluid | L9 slide 26 |
| Thiazide diuretics chlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide | Hypokalemia (and magnesium loss) and metabolic alkalosis from the contracted extracellular fluid. | Monitor potassium; keep it above 4.0 mEq per liter in anyone taking digoxin. | Electrolytes / Acid-base | L9 slide 26 |
| Thiazide diuretics chlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide | Hyperuricemia and gout. | Ask about a history of gout. | Metabolic / Musculoskeletal | L9 slide 26 |
| Thiazide diuretics chlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide | Hyperglycemia (lower glucose tolerance and decreased insulin secretion). | Monitor blood glucose in diabetes. | Metabolic | L9 slide 27 |
| Thiazide diuretics chlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide | Hypercalcemia: less calcium is excreted, so serum calcium can rise slightly. | Monitor calcium in patients with hypercalcemia or parathyroid disease. | Electrolytes | L9 slide 27 |
| Thiazide diuretics chlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide | Hyperlipidemia: low-density lipoprotein (LDL) cholesterol rises by roughly 5 to 15 percent. | Lipids may be checked during long-term use. | Metabolic | L9 slide 27 |
| Thiazide diuretics chlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide | Allergic skin rashes and photosensitivity. | Counsel on sun protection and to report a rash. | Dermatologic | L9 slide 27 |
| Thiazide diuretics chlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide | Dizziness, headaches, weakness and restlessness. | Ask about these symptoms; they are usually mild. | Neurologic | L9 slide 27 |
| Thiazide diuretics chlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide | Sexual dysfunction and constipation. | Ask directly; patients rarely volunteer sexual symptoms and may stop the drug. | Genitourinary / Gastrointestinal | L9 slide 28 |
| Potassium-sparing diuretics | ||||
| Potassium-sparing diuretics amiloride, triamterene | Hyperkalemia: the characteristic adverse effect, and the major difference from other diuretics. Use caution with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and potassium supplements. | Monitor serum potassium and kidney function. Added background: warn about potassium-rich foods and salt substitutes, which are usually potassium chloride. | Electrolytes | L9 slide 33 |
| Potassium-sparing diuretics amiloride, triamtereneBlack box | Hyperkalemia, which can be fatal. Added background: FDA boxed warning (black box) for amiloride and triamterene. | Check potassium early and regularly; stop and treat a rising level. | Electrolytes / Cardiovascular | L9 slide 33 |
| Potassium-sparing diuretics amiloride, triamterene | Diabetes: glucose intolerance. | Monitor blood glucose in diabetes. | Metabolic | L9 slide 33 |
| Triamterene unique effect | Megaloblastic anemia. | Watch for fatigue and pallor; a blood count and folate level can be checked. | Hematologic | L9 slide 33 |
| Amiloride unique effect | Azotemia (a rise in blood urea nitrogen). | Monitor kidney function. | Renal | L9 slide 33 |
| Aldosterone antagonists | ||||
| Aldosterone antagonists spironolactone, eplerenone | Hyperkalemia and mild acidosis. | Monitor potassium, especially with kidney disease, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. | Electrolytes / Acid-base | L9 slide 38 |
| Aldosterone antagonists spironolactone, eplerenone | Nausea, vomiting and gastrointestinal upset. | Take with food if upset occurs. | Gastrointestinal | L9 slide 38 |
| Spironolactone androgen-receptor effects | Hormonal effects at the androgen (testosterone) receptor. Men: gynecomastia and testicular atrophy. Women: menstrual irregularities (hirsutism is also listed). Gynecomastia occurs in about 10 percent of men in heart failure. Added background (truth over the course wording): the course calls spironolactone a weak partial agonist at the androgen receptor, but in current pharmacology it blocks that receptor (and has some progesterone-like activity). That explains the breast and sexual effects in men and the menstrual changes; hirsutism is not a typical effect, because spironolactone is used to treat hirsutism and acne. | Ask about breast tenderness, breast enlargement and menstrual changes; switch to eplerenone if these occur, because it has less effect on androgen receptors. | Endocrine / Reproductive | L9 slide 38 |
| Carbonic anhydrase inhibitors | ||||
| Carbonic anhydrase inhibitors acetazolamide, dichlorphenamide, methazolamide | Metabolic acidosis (bicarbonate is lost in the urine), unlike the contraction alkalosis of other diuretics. | Monitor serum bicarbonate. | Acid-base | L9 slide 43 |
| Carbonic anhydrase inhibitors acetazolamide, dichlorphenamide, methazolamide | Potassium depletion. | Monitor serum potassium. | Electrolytes | L9 slide 43 |
| Carbonic anhydrase inhibitors acetazolamide, dichlorphenamide, methazolamide | Drowsiness. | Counsel about drowsiness before driving. | Neurologic | L9 slide 43 |
| Heart failure: diuretics, ACE inhibitors and beta blockers | ||||
| ACE (angiotensin-converting enzyme) inhibitors in heart failure | Impairment of renal function (an acute decrease in kidney function). | Check creatinine and potassium at the start and after dose changes. | Renal | L9 slide 56 |
| ACE (angiotensin-converting enzyme) inhibitors in heart failure | Hypotension, particularly with other blood-pressure-lowering drugs. | Check blood pressure; warn about dizziness on standing. | Cardiovascular | L9 slide 56 |
| ACE (angiotensin-converting enzyme) inhibitors in heart failure | Elevation of serum potassium. A loop diuretic lowers potassium while these raise it, so the balance must be checked. | Monitor potassium. | Electrolytes | L9 slide 56 |
| ACE (angiotensin-converting enzyme) inhibitors in heart failure | Cough (dry cough). | Ask about a persistent dry cough; an angiotensin receptor blocker avoids it. | Respiratory | L9 slide 56 |
| ACE (angiotensin-converting enzyme) inhibitors in heart failure | Angioedema: swelling of the lips, tongue or throat. | Teach the patient to seek urgent help for swelling of the face or tongue; stop the drug. | Immunologic / Airway | L9 slide 56 |
| ACE (angiotensin-converting enzyme) inhibitors in heart failureBlack box | Added background: all angiotensin-converting enzyme inhibitors carry an FDA boxed warning (black box) for fetal toxicity (injury and death of the developing fetus). | Confirm the patient is not pregnant before starting; counsel on contraception. | Reproductive / Fetal | L9 slide 56 |
| Beta blockers in heart failure carvedilol, metoprolol succinate, bisoprolol | Worsening heart failure if started in an unstable patient or raised too fast: beta blockers lower heart rate and contractility, so the patient can decompensate. | Monitor for worsening heart failure signs and symptoms and for fluid accumulation (weight). | Cardiovascular | L9 slide 58 |
| Beta blockers in heart failure carvedilol, metoprolol succinate, bisoprololBlack box | Added background: beta blockers must not be stopped abruptly (rebound angina, arrhythmia, myocardial infarction). Metoprolol carries an FDA boxed warning (black box) for abrupt cessation; carvedilol and bisoprolol carry no boxed warning but give the same caution. | Never stop abruptly. Ask about missed doses and running out of medicine. | Cardiovascular | L9 slide 58 |
| Digoxin | ||||
| Digoxin cardiac glycoside | Gastrointestinal: anorexia and nausea. | Check a digoxin level and electrolytes when nausea or anorexia appears in a patient taking digoxin. | Gastrointestinal | L9 slide 68 |
| Digoxin cardiac glycoside | Visual disturbances: blurred vision, photophobia, xanthopsia (yellow-green tinge) and yellow-green halos or shining lights around objects. | Ask every patient on digoxin about visual change; yellow-green halos should prompt a drug level right away. | Sensory | L9 slide 68 |
| Digoxin cardiac glycoside | Central nervous system: delirium, fatigue, confusion, dizziness and abnormal dreams. | Suspect toxicity in an older patient with new confusion or fatigue; check the level. | Neurologic | L9 slide 69 |
| Digoxin cardiac glycoside | Cardiac: nodal slowing with a longer PR interval and shorter QT interval, ST-segment depression, bradycardia and digoxin-induced afterdepolarizations. Almost any arrhythmia can occur, including premature ventricular beats. | Monitor pulse and the electrocardiogram; bradycardia and heart block are classic toxic findings. | Cardiovascular | L9 slide 70 |
| Digoxin cardiac glycoside | Toxicity risk rises with low potassium, low magnesium and high calcium. Added background: digoxin has a narrow therapeutic window, and kidney impairment also raises toxicity risk because digoxin is cleared by the kidneys. | Drug levels are checked for digoxin; keep potassium and magnesium normal. | Toxicity | L9 slide 65 |
| Other heart failure drugs | ||||
| Phosphodiesterase (type III) inhibitors milrinone, inamrinone | Thrombocytopenia (less with milrinone) and ventricular arrhythmias. | Monitor platelet count and cardiac rhythm during infusion. | Hematologic / Cardiovascular | L9 slide 76 |
| Phosphodiesterase (type III) inhibitors milrinone, inamrinone | Long-term use raises mortality and morbidity compared with placebo. | Used only short term in hospital. | Cardiovascular | L9 slide 76 |
| Ivabradine hyperpolarization-activated channel blocker | Increased risk of atrial fibrillation and symptomatic bradycardia. | Monitor heart rate and rhythm; report palpitations or dizziness. | Cardiovascular | L9 slide 80 |
| Ivabradine hyperpolarization-activated channel blocker | Visual impairment (phosphenes): a transient brightness in a limited area of the visual field, halos or multiple images, from an effect on retinal photoreceptors (retinal persistency). It can resolve on its own. | Warn about driving at night or in changing light; usually resolves. | Sensory | L9 slide 80 |
| Sacubitril-valsartan neprilysin inhibitor with an angiotensin receptor blocker | The most common adverse effects: hypotension, hyperkalemia, cough and renal insufficiency. | Check blood pressure, potassium and kidney function. | Cardiovascular / Electrolytes / Renal | L9 slide 81 |
| Sacubitril-valsartan neprilysin inhibitor with an angiotensin receptor blockerBlack box | Added background: sacubitril-valsartan carries an FDA boxed warning (black box) for fetal toxicity. | Confirm the patient is not pregnant; counsel on contraception. | Reproductive / Fetal | L9 slide 81 |
| Sodium-glucose cotransporter 2 (SGLT2) inhibitors dapagliflozin, empagliflozin | Hypotension (blood volume falls as sugar and fluid are passed in the urine) and fungal infections of the genital and urinary tract. | Check blood pressure and volume status; ask about genital itching, discharge and urinary symptoms. | Cardiovascular / Genitourinary | L9 slide 82 |
| Drug or class | Side effects | Monitoring & what to watch | System | Source |
|---|---|---|---|---|
| Principles and classification | ||||
| All antiarrhythmics proarrhythmia | All antiarrhythmics may induce arrhythmias. | Understand the mechanism and weigh the goal (termination or prevention) against the risk; remove precipitating factors first. | Cardiovascular | L10 slide 3 |
| Class IA: quinidine, procainamide, disopyramide | ||||
| Quinidine class IA | Nausea, vomiting and diarrhea (30 to 50 percent). | The most common reason the drug is poorly tolerated. | Gastrointestinal | L10 slide 11 |
| Quinidine class IABlack box | Arrhythmias (ventricular and atrial), quinidine sudden death, torsades de pointes (2 to 8 percent). Added background (not on the slides): quinidine carries a Food and Drug Administration (FDA) boxed warning for increased mortality when it is used for arrhythmias that are not life-threatening. | Watch the rhythm and the QT interval; magnesium sulfate is the treatment of torsades. | Cardiovascular | L10 slide 11 |
| Quinidine class IA | Hypotension (alpha blockade at higher doses) and anticholinergic effects. | Blood pressure. | Cardiovascular / Autonomic | L10 slide 11 |
| Quinidine class IA | Thrombocytopenia (may be fatal); immunological reactions. | Platelet count; report bruising or bleeding. | Blood / Immune | L10 slide 11 |
| Quinidine class IA | Cinchonism: tinnitus, dizziness, blurred vision. | Ask about ringing in the ears and vision. | Nervous system / Ear and eye | L10 slide 11 |
| Procainamide class IA | Hypotension, slowing of conduction, nausea, torsades de pointes. | Blood pressure and the rhythm. Intravenous use is better tolerated than quinidine; oral use is poorly tolerated long term. | Cardiovascular / Gastrointestinal | L10 slide 13 |
| Procainamide class IABlack box | Lupus-like syndrome (25 to 50 percent), more often in slow acetylators. Added background (not on the slides): procainamide carries an FDA boxed warning for a positive antinuclear antibody test, with or without a lupus-like syndrome. | Acetylator status matters: slow acetylators accumulate the drug; fast acetylators make more of the active metabolite (N-acetylprocainamide, NAPA). | Immune | L10 slide 13 |
| Procainamide class IABlack box | Bone marrow suppression (0.2 percent). Added background (not on the slides): the same boxed warning covers blood dyscrasias such as agranulocytosis. | Blood counts. | Blood | L10 slide 13 |
| Disopyramide class IA | Hypotension, antimuscarinic effects, conduction disturbances, torsades de pointes. | Blood pressure and the rhythm; its anticholinergic actions are stronger than quinidine's. | Cardiovascular / Autonomic | L10 slide 15 |
| Disopyramide class IA | Congestive heart failure from decreased contractility (a negative inotropic effect). | Watch for signs of heart failure. | Cardiovascular | L10 slide 15 |
| Class IB: lidocaine | ||||
| Lidocaine class IB | Central nervous system toxicity: drowsiness, confusion, restlessness, muscle twitches, seizures; nystagmus is an early sign of toxicity. | Look for nystagmus as the first sign of toxicity. | Nervous system | L10 slide 19 |
| Lidocaine class IB | Hypersensitivity; increases atrioventricular conduction. | Allergy history. | Immune / Cardiovascular | L10 slide 19 |
| Class IC: flecainide, propafenone | ||||
| Flecainide class ICBlack box | Increased mortality after myocardial infarction; ventricular tachycardia resistant to treatment. Added background (not on the slides): flecainide carries an FDA boxed warning, from the Cardiac Arrhythmia Suppression Trial, for excess mortality or nonfatal cardiac arrest after myocardial infarction, and for proarrhythmic effects. | Use only without significant structural damage to the heart. | Cardiovascular | L10 slide 23 |
| Flecainide class IC | Blurred vision, tremor, bronchospasm, seizures, thrombocytopenia. | Breathing in patients with asthma; platelet count. | Nervous system / Respiratory / Blood | L10 slide 23 |
| Propafenone class ICBlack box | Proarrhythmic. Added background (not on the slides): propafenone carries the same FDA boxed warning for mortality from the Cardiac Arrhythmia Suppression Trial. | The rhythm. | Cardiovascular | L10 slide 24 |
| Propafenone class IC | Dizziness, blurred vision, bradycardia; bronchospasm (beta-adrenergic blockade); agranulocytosis, anemia, thrombocytopenia; worsens heart failure. | Heart rate, breathing and blood counts. | Cardiovascular / Respiratory / Blood | L10 slide 24 |
| Class II: beta blockers | ||||
| Propranolol class II; nonselective | Heart failure, heart block, hypotension, bronchospasm; digitalis toxicity. Hyperglycemia is also listed (see the study guide on the glucose point). | Heart rate, blood pressure, breathing; signs of heart failure. | Cardiovascular / Respiratory | L10 slide 28 |
| Metoprolol, acebutolol class II; beta-1 selective | Less bronchospasm than propranolol; congestive heart failure; central nervous system sedation and fatigue. | Tiredness and sedation; signs of heart failure. | Nervous system / Cardiovascular | L10 slide 29 |
| Class III: amiodarone, dofetilide, sotalol | ||||
| Amiodarone class IIIBlack box | Pneumonitis and pulmonary fibrosis (potentially fatal). Added background (not on the slides): amiodarone carries an FDA boxed warning for pulmonary toxicity, hepatic injury and worsened arrhythmia, and is reserved for life-threatening arrhythmias. | Ask about cough and breathlessness. | Respiratory | L10 slide 33 |
| Amiodarone class IIIBlack box | Hepatic dysfunction. Added background (not on the slides): part of the same boxed warning (hepatic injury). | Liver tests. | Liver | L10 slide 33 |
| Amiodarone class III | Thyroid abnormalities (hyperthyroidism or hypothyroidism): amiodarone is an analog of thyroid hormone. | Thyroid function. | Endocrine | L10 slide 33 |
| Amiodarone class III | Blue-gray skin color, photosensitivity; corneal deposits. | Sun protection; eye checks. | Skin / Eye | L10 slide 33 |
| Amiodarone class III | Hypotension; neurotoxicity, neuropathy, muscle weakness, ataxia. | Blood pressure; gait and strength. | Cardiovascular / Nervous system | L10 slide 33 |
| Dofetilide class IIIBlack box | Torsades de pointes (1 to 3 percent); marked QT prolongation. Added background (not on the slides): dofetilide carries an FDA boxed warning: it must be started in a facility with creatinine clearance calculated and continuous electrocardiogram monitoring. | QT interval; kidney function (it is mainly eliminated unchanged by the kidneys). Prescribing is limited to those with special training. | Cardiovascular | L10 slide 34 |
| Sotalol class III with beta-blocking activityBlack box | Torsades de pointes; bronchospasm; beta-blocking effects. Added background (not on the slides): sotalol carries an FDA boxed warning: start it where the electrocardiogram can be monitored, because of QT prolongation and torsades de pointes. | QT interval; breathing. | Cardiovascular / Respiratory | L10 slide 36 |
| Class IV: verapamil, diltiazem | ||||
| Verapamil, diltiazem class IV | Hypotension, edema. | Blood pressure and ankle swelling; liver function (hepatic metabolism). | Cardiovascular | L10 slide 39 |
| Miscellaneous: adenosine, digoxin, magnesium sulfate | ||||
| Adenosine miscellaneous | Flushing (20 percent), shortness of breath, burning in the chest; it may stop the heart for 2 to 3 seconds. | Continuous rhythm monitoring while it is given; effects pass quickly (half-life about 10 seconds). | Skin / Respiratory / Cardiovascular | L10 slide 42 |
| Digoxin miscellaneous | Nausea, vomiting, diarrhea, anorexia. | Gastrointestinal symptoms are often the first complaint. | Gastrointestinal | L10 slide 44 |
| Digoxin miscellaneous | Central nervous system: confusion, delirium, headache, seizures, visual disturbances. It can also induce heart block. | Mental status and vision; heart rate and atrioventricular conduction. | Nervous system / Eye / Cardiovascular | L10 slide 44 |
| Magnesium sulfate miscellaneous | Bradycardia, flushing, headache; respiratory paralysis. | Heart rate and breathing. | Cardiovascular / Respiratory | L10 slide 45 |
| Drug or class | Side effects | Monitoring & what to watch | System | Source |
|---|---|---|---|---|
| Acute bronchitis | ||||
| Antihistamines, sympathomimetics in acute bronchitis | Dehydrate bronchial secretions; may prolong symptoms. | Possibly avoid them in acute bronchitis. | Respiratory | L11 slide 7 |
| Antipseudomonal agents, aminoglycosides, vancomycin and linezolid | ||||
| Imipenem/cilastatin carbapenem | Seizures. | Use with caution in a seizure history; meropenem carries less seizure risk. | Nervous system | L11 slide 25 |
| Aminoglycosides gentamicin, tobramycin, amikacin | Ototoxicity and nephrotoxicity. | Drug levels guide dose and frequency; highly dependent on renal function. | Ear / Kidney | L11 slide 28 |
| Vancomycin glycopeptide | Ototoxicity; nephrotoxic, especially with other nephrotoxins. | Trough before the third or fourth dose (steady state); renal adjustment. | Ear / Kidney | L11 slide 29 |
| Nosocomial (hospital-acquired) pneumonia | ||||
| Antibiotic therapy nosocomial pneumonia | Complications: C. difficile colitis, empyema or lung abscess (one of the three reasons therapy fails, with wrong therapy and wrong diagnosis). | Scale back coverage as cultures return. | Gastrointestinal / Respiratory | L11 slide 31 |
| Tuberculosis drugs | ||||
| Isoniazid tuberculosis | Peripheral neuritis from pyridoxine deficiency. | Give pyridoxine (vitamin B6). | Nervous system | L11 slide 39 |
| Isoniazid tuberculosis | Hepatitis, increased in alcoholics and with age. | Ask about alcohol use; liver tests, especially in older patients. | Liver | L11 slide 39 |
| Isoniazid tuberculosis | Allergic reactions: a lupus-like syndrome. | Listed as an allergic reaction to isoniazid. | Immune | L11 slide 39 |
| Isoniazid tuberculosis | Central nervous system: seizures, euphoria, psychosis, memory impairment. | It is well absorbed and enters the central nervous system. | Nervous system | L11 slide 39 |
| Rifampin tuberculosis | Orange secretions: tears, sweat, urine. | Warn the patient in advance. | Skin / Secretions | L11 slide 42 |
| Rifampin tuberculosis | Induces cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP3A4), lowering anticoagulants, contraceptives, chloramphenicol, digoxin, ketoconazole and theophylline. | Review every other drug the patient takes: contraceptives and anticoagulants are on the list. | Drug interactions | L11 slide 42 |
| Rifampin tuberculosis | Jaundice and hepatitis, a concern in chronic liver disease. | Liver tests. | Liver | L11 slide 42 |
| Rifampin tuberculosis | Hypersensitivity: a flu-like syndrome in 20 percent of patients; gastrointestinal disturbances. | Tell the patient it can happen. | Immune / Gastrointestinal | L11 slide 42 |
| Ethambutol tuberculosis | Visual disturbances: decreased red-green discrimination and decreased visual acuity. | Ask about vision and color perception. | Eye | L11 slide 44 |
| Ethambutol tuberculosis | Increased uric acid levels. | 75 percent is excreted unchanged: adjust in renal disease. | Metabolic | L11 slide 44 |
| Pyrazinamide tuberculosis | Hepatitis (15 percent). | Monitor liver enzymes; given for the first two months only to limit liver toxicity. | Liver | L11 slide 45 |
| Pyrazinamide tuberculosis | Inhibits uric acid excretion: every patient becomes hyperuricemic. | Ask about gout symptoms. | Metabolic | L11 slide 45 |
| Streptomycin second-line tuberculosis; not tested | Auditory and vestibular toxicity. | Hearing and balance. | Ear | L11 slide 46 |
| Aminosalicylic acid second-line tuberculosis; not tested | Gastrointestinal problems. | Ask about stomach upset. | Gastrointestinal | L11 slide 46 |
| Cycloserine second-line tuberculosis; not tested | Central nervous system: psychosis, seizures. | Watch mood, behavior and for seizures. | Nervous system | L11 slide 46 |
| Anaphylaxis | ||||
| Epinephrine anaphylaxis | Anxiety, hypertension, tachycardia, nausea and vomiting, diaphoresis. | Intramuscular is preferred unless the patient is coding. | Cardiovascular | L11 slide 52 |
| Epinephrine overdose | Overdose: cerebrovascular hemorrhage, myocardial infarction, pulmonary edema. | Two concentrations exist and differ tenfold: confirm which is drawn up. | Cardiovascular / Nervous system | L11 slide 52 |
| Albuterol anaphylaxis | Anxiousness, tremor, tachycardia. | Expected with a beta-2 agonist. | Cardiovascular / Nervous system | L11 slide 54 |
| Asthma: quick relief and bronchodilators | ||||
| Beta-2 agonists albuterol, levalbuterol, formoterol, salmeterol | Tachycardia, hypotension, headache, dizziness, insomnia, tremors, hyperglycemia. | Increased heart rate and tremor are the expected ones; overuse of the short-acting drug means poor control. | Cardiovascular / Metabolic | L11 slide 71 |
| Theophylline methylxanthine | Arrhythmias, convulsions, headaches, nausea, insomnia, heartburn; it stimulates gastric acid, has diuretic effects and relaxes smooth muscle. | Narrow therapeutic index: monitor plasma levels. As levels rise: nausea, vomiting and cardiac effects first, then seizures and arrhythmias. (The slides give level bands; their units differ between the two slides.) | Cardiovascular / Nervous system / Gastrointestinal | L11 slide 82 |
| Anticholinergics ipratropium, tiotropium | Blind as a bat (blurry vision, mydriasis), mad as a hatter (hallucinations, delirium, memory loss, psychosis), red as a beet (flushing), hot as Hades (fever, hyperthermia), dry as a bone (dry mouth, dry eyes); the bowel and bladder lose their tone (constipation, urinary retention); the heart runs alone (tachycardia, hypertension). | Teach the patient the dry mouth, blurred vision and urinary retention to report. | Autonomic | L11 slide 87 |
| Asthma: long-term controllers and systemic steroids | ||||
| Inhaled corticosteroids controllers | Oral candidiasis (thrush). | Look in the mouth at follow-up. | Mouth / Infection | L11 slide 73 |
| Inhaled corticosteroids controllers | Growth suppression in children (high dose); immune inhibition (systemic action). | Track growth in children on high doses. | Endocrine / Immune | L11 slide 73 |
| Montelukast leukotriene receptor antagonist | Side effects listed as minimal and well tolerated. Current labeling differs: a FDA (Food and Drug Administration) boxed warning (2020) for serious neuropsychiatric events such as agitation, depression and suicidal thoughts. | Ask about mood and behavior changes. | Nervous system | L11 slide 75 |
| Omalizumab anti-immunoglobulin EBlack box | Anaphylaxis (0.1 percent). Added background (not on the slides): also a FDA (Food and Drug Administration) boxed warning; the slides list anaphylaxis among its adverse effects. | Watch the patient after each injection. | Immune | L11 slide 79 |
| Omalizumab anti-immunoglobulin E | Gastrointestinal disturbances; neutralizing antibodies may develop; secondary malignancies; urticaria (0.1 percent); injection-site pain; bruising. | Similar profile for mepolizumab, benralizumab, reslizumab and dupilumab. | Immune / Gastrointestinal / Skin | L11 slide 79 |
| Systemic corticosteroids prednisone and others | Adrenal suppression. The general rule given: taper if the course lasts more than 5 days. References differ on the cutoff: many taper only after longer courses. | Do not stop a long course abruptly. | Endocrine | L11 slide 89 |
| Systemic corticosteroids prednisone and others | Growth suppression, dermal thinning, hypertension, hyperglycemia, altered mood or mental status, muscle weakness (steroid myopathy), immunosuppression. | The reason systemic steroids are kept for exacerbations: most potent, limited by side effects. | Endocrine / Metabolic / Musculoskeletal | L11 slide 89 |
| Inhaler devices, technique and status asthmaticus | ||||
| Nebulizer device | A bigger dose is given overall, which may lead to more side effects. | Clean regularly to prevent microbial growth. | Device | L11 slide 92 |
| Ketamine status asthmaticus, if intubated | Emergence phenomenon, hypertension, tachycardia, vomiting. | Used only once the patient is intubated. | Nervous system / Cardiovascular | L11 slide 99 |
| Chronic obstructive pulmonary disease, smoking cessation and vaccines | ||||
| Nicotine replacement patch, gum, spray, inhaler | Tachyarrhythmias and hypertension. | Caution in patients with cardiovascular problems. | Cardiovascular | L11 slide 106 |
| Varenicline smoking cessation | Nausea, sleep disturbance, headache. | Start one week before the quit date. | Gastrointestinal / Nervous system | L11 slide 107 |
| Varenicline smoking cessationBlack box | Black box warning: neuropsychiatric events (depression, suicidal ideation). Current labeling differs: the FDA (Food and Drug Administration) removed this boxed warning in 2016; neuropsychiatric events stay in the warnings. | Ask about mood and suicidal thoughts at each visit. | Psychiatric | L11 slide 107 |